Romidepsin (FK228, Depsipeptide)

For research use only. Not for use in humans.

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別) 在庫  
JPY 28000 あり
JPY 81100 あり
JPY 117700 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(97)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NULEeohFS2WubDDWbYFjcWyrdImgRZN{[Xl? NYLycFZ1Oi53LUG1JI5O NWTLTG12PzJiaB?= NV;2VlhwcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M3vIR|I2PzlyOUC3
U2932  MnPVR4VtdCCYaXHibYxqfHliQYPzZZk> NVr6XplqOi53LUG1JI5O MYG3NkBp NWjuSGM5cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MUCyOVc6ODlyNx?=
OCI-LY7 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoD1Nk42NTF3IH7N NUXBN5dXPzJiaB?= MkPEbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MWWyOVc6ODlyNx?=
Farage M2jsfWNmdGxiVnnhZoltcXS7IFHzd4F6 NULzXGdNOi53LUG1JI5O NYrGZmI5PzJiaB?= MlHUbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MkfCNlU4QTB7MEe=
LY7/EBV Mn;SR4VtdCCYaXHibYxqfHliQYPzZZk> MWKyMlUuOTVibl2= Mlm0O|IhcA>? NGjHcpVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NH3sO5ozPTd7MEmwOy=>
U2932/EBV NYPYV3dtS2WubDDWbYFjcWyrdImgRZN{[Xl? NHLrWlYzNjVvMUWgcm0> NYXlZo1CPzJiaB?= M1vNUIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NHH4WlYzPTd7MEmwOy=>
HCT116 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3cVhqPS13MECwJI5O NVHkbopuOjRiaB?= NFLVZ3JFVVOR MXzpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NHr1cWczPTR7MkWxOS=>
ACH-2 MYTGeY5kfGmxbjDBd5NigQ>? MnTkNU06KG6P NGrsZYozPCCq NI\nNYJqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v MWiyOVE1QTR4Nx?=
MCF-10A NUfo[21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfwTHZnUUN3ME2wMlE4yrFyLkCxJI5O NV3EeZU{OjR7NUS4OVY>
MCF-7 NWn6ZVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjKcIRYUUN3ME2xMlExyrFyLkKwJI5O MWKyOFk2PDh3Nh?=
SK-BR-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInBTIJKSzVyPUGuNFDDuTBwM{Wgcm0> MWOyOFk2PDh3Nh?=
MDA-MB-231 M3\SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTkTWM2OD1yLk[4xtExNjF2IH7N MlrBNlQ6PTR6NU[=
PC3 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwNkZCtVAvOzVibl2= MVWyOFk2PDh3Nh?=
HCT116 NVW4TlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPFcWFlUUN3ME2xMlAxyrFyLkCwJI5O NVPxS4FEOjR7NUS4OVY>
HCT116-p21-/- NYfBTXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVTWlEPTB;MT6yOuKyOC5|NzDuUS=> MW[yOFk2PDh3Nh?=
S1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofCTWM2OD15Lk[3xtExNjJ7IH7N NUnFVYZLOjR7NUS4OVY>
SW620 M125[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwOURCtVAvOjlibl2= M1OzfVI1QTV2OEW2
LOX-IMVI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:ybGlEPTB;MD64O:KyOC5yMzDuUS=> MlTwNlQ6PTR6NU[=
UACC-62 NVjqNlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[wTmlqUUN3ME2wMlU3yrFyLkG2JI5O NIC0VZczPDl3NEi1Oi=>
MDA-MB-435 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC3c5hKSzVyPUCuPVDDuTBwME[gcm0> Mln0NlQ6PTR6NU[=
SF-295 NUnme3pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfTTWM2OD1yLki4xtExNjF3IH7N M{[wVVI1QTV2OEW2
A549 NVu0WYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi5Vo1KSzVyPUGuNlbDuTBwMkSgcm0> M1K1WlI1QTV2OEW2
H460 NHvFNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnCRYRKSzVyPUKuOVjDuTBwOECgcm0> NIrmfHIzPDl3NEi1Oi=>
EKVX NFH3TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml20TWM2OD1zLkOzxtExNjN2IH7N M3G2RVI1QTV2OEW2
H146 M1;INGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMkNCtVAvODdibl2= NXPvWI5KOjR7NUS4OVY>
H526 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;WTWM2OD1yLkG1xtExNjB|IH7N M3nCVVI1QTV2OEW2
HuT-78 M4HicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwN{RCtVAvPDRibl2= NYn1d2d2OjR7NUS4OVY>
HA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KUZR6OC54MkWtNVBvVQ>? NX;F[pQyPDhiaB?= NFXwZnpqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? M3HTdFI1PzdzNUGw
MS-275 NHzhVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLZVnMxNjZ{NT2xNI5O NVvuXmM3PDhiaB?= M4\sR4lv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj MYOyOFc4OTVzMB?=
CD4 T M1fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK0PEBp MX7FR|UxRTRwNdMxNU4xKG6P NHPNTWIzPDd{MkS1OC=>
CD4 T NH3USpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\icHY1QCCq NIjCRpBESzVyPUGwO:KyOTJ4IH7N NITuVVgzPDd{MkS1OC=>
CD4+ T NGLaSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLFR|UxRTNibl2= M{D0OFI1PDl3MUC1
A549 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxNQKBmzFyMNMgcm0> NVG0fmFuOjRxM{[vOFghcA>? M{\O[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M13G[lI1PDh3N{m5
JJN3 NWHkZ2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCyOE81QCCq NHj4O4pGSzVyPEJihKlvVTtiNElihKlp MVuyOFA{ODF3MB?=
OPM-2 NF\wVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3cWpZOjRxNEigbC=> MULFR|Uxez1z4pEJcm08KDR64pEJbC=> NGjzTJYzPDB|MEG1NC=>
RPMI-8226 M3n3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGyOE81QCCq MYDFR|Uxez1zLklihKlvVTtiNElihKlp NWHP[WFzOjRyM{CxOVA>
U266 NF\4cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLlUIo5OjRxNEigbC=> NGHVc5dGSzVyc{2xNQKBkW6POzC0PQKBkWh? NIrFNJgzPDB|MEG1NC=>
CA46 NVm5WWZ5SXCxcITvd4l{KEG|c3H5 NHzRVFY3KGh? NFvIcIxqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NYHrU|BsOjN7Nk[xOlQ>
DG75 NGD4VJhCeG:ydH;zbZMhSXO|YYm= MnrZOkBp Mn7mbY5lfWOnczDuc{BieG:ydH;zbZM> MUCyN|k3PjF4NB?=
Ramos NW\DXVZoSXCxcITvd4l{KEG|c3H5 MlXrOkBp NVfrfVJLcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MVeyN|k3PjF4NB?=
ST486 NYXRRo5kSXCxcITvd4l{KEG|c3H5 MV:2JIg> NWDhT2p7cW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NHPpSmgzOzl4NkG2OC=>
HuT78 MlfDRZBweHSxc3nzJGF{e2G7 MlnaNU8yOC9zMECgcm0> MkXoOFghcA>? MUTpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P NIPKT48zOzV|MkezNi=>
DpVp35 M3W0PWFxd3C2b4Ppd{BCe3OjeR?= MljZNU8yOC9zMECgcm0> MkXPOFghcA>? MVjpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NIHLcVczOzV|MkezNi=>
DpVp50 NIH3dG5CeG:ydH;zbZMhSXO|YYm= NVLh[Xc3OS9zMD:xNFAhdk1? NFLFZnE1QCCq MVnpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MnzDNlM2OzJ5M{K=
DpP75  NFLKbZJCeG:ydH;zbZMhSXO|YYm= MXGxM|ExNzFyMDDuUS=> M1j2UFQ5KGh? MWHpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NXnjS2FpOjN3M{K3N|I>
SKOV-3 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3[5Ay6oDVMkDuUS=> MVy3NkBp NV;FNZFKTE2VTx?= NHjOcJlz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MnPINlMxOTB|NEi=
Brca1 WT NETIbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7QfIIy6oDVMkDuUS=> M13mTFczKGh? MXXEUXNQ M3\acZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M3fxVFI{ODFyM{S4
Brca1 Null MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLwNgKBmzJybl2= MlzPO|IhcA>? NWjJcm1sTE2VTx?= NVPiU5VOemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MoHjNlMxOTB|NEi=
OVCAR-8  NHnzZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\FdVky6oDVMkDuUS=> MVm3NkBp M3vMdGROW09? Mnv2doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M2\aflI{ODFyM{S4
NCI/ADR-RES NHS5b3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXix5qCUOjCwTR?= NUXje|dVPzJiaB?= M4nPRmROW09? MWDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M1jLUlI{ODFyM{S4
HCT116 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nyU|Uhdk1vNUCg{txO NEjlNYUzPCCq MUXEUXNQ M1;EdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NX[5[4hSOjJ7MkS5OVg>
RKO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrRN3R[PSCwTT21NEDPxE1? MXyyOEBp NVPU[oRrTE2VTx?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NV\5Ro9LOjJ7MkS5OVg>
CO115 NYLEPWt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoOUBvVS13MDFOwG0> MnLjNlQhcA>? MVHEUXNQ MoXBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MkfvNlI6OjR7NUi=
HFS NVm3NnV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLwOUBvVQ>? M{jxeVI1NzR6L{eyJIg> NWfwRW9kcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NYryRWhzOjJzME[yPFI>
LNCaP MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn33OUBvVQ>? MUeyOE81QC95MjDo NEf1TlRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MnfSNlIyODZ{OEK=
A549 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj4OUBvVQ>? NWLyUpZtOjRxNEivO|IhcA>? MUTpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 Ml;rNlIyODZ{OEK=
697  M1nZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fDdWlEPTEkgJm95qCKOi53wrDuUS=> Mn;UNlE2Ozh{MU[=
697-R MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OOLCiU5ihKk5NjcEoH7NxsA> MorzNlE2Ozh{MU[=
HUT78 M4[1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fSXmlEPTB;MTDuUS=> MWGyNVE6QDV2NR?=
THJ-16T MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV60dWxqOSCwTR?= Mn7zNlQhcA>? NU\BTmZmcW6qaXLpeJMh[2WubDDndo94fGh? NWm1eFBUOjB6MUC1Olg>
HCT116 Mnm3SpVv[3Srb36gRZN{[Xl? Ml;FNlAhdk1? MV64JIg> NIm0XG9ud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= MV6yNFc{QTR3NB?=
B104  NWC2U4prTnWwY4Tpc44hSXO|YYm= NUfjdVNXOiCwTR?= Mnq5NlQwPDhxN{KgbC=> Ml75bY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi MXuyNFY5PjVyNR?=
HL-60  NEO4ZoNEgXSxdH;4bYNqfHliQYPzZZk> NFLCblgyNTVyMDDuUS=> NHzKOYszPCCq MoHvbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NWny[YVOOjB4MkSxOlM>
HP100 NF;TWIVEgXSxdH;4bYNqfHliQYPzZZk> M4LrfVEuPTByIH7N NWTvR3VrOjRiaB?= MX\pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MYeyNFYzPDF4Mx?=
HL-60  MWDGeY5kfGmxbjDBd5NigQ>? NEnVXmoyOCCwTR?= Mk\hOE83NzF4IHi= NFvYXWZqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= MnrONlA3OjRzNkO=
HP100 NVXpe|lrTnWwY4Tpc44hSXO|YYm= M33xOVExKG6P NUnJZodkPC94L{G2JIg> NUXVXolOcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NGLCfIMzODZ{NEG2Ny=>
HL-60  MV\GeY5kfGmxbjDBd5NigQ>? NUPOWWR{OTBvNUCwJI5O NUTzU2hGPCCq Mley[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NXnmbHFJOjB4MkSxOlM>
HP100 MmDISpVv[3Srb36gRZN{[Xl? M{f1PVExNTVyMDDuUS=> Ml\0OEBp NVuwV|I2\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg Ml\LNlA3OjRzNkO=
11z MlLHT4lv[XOnIFHzd4F6 NULQN|RLOy1zMECgcm0> M1fiPZJm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr NWDJbnJiOjB4MEWxOFQ>
SKOV-3 NXLuXmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm0M|gwOTZibl2= NFO0VII1QCCq MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M4TmblIxPDB2NU[0
OVCAR-3 NF7RZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\oW|A1NzhxMU[gcm0> MXK0PEBp M32xbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NHT6Zo0zODRyNEW2OC=>
HBL-2 M3fXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M123blIuOTBibl2= M1y3UFI1KGh? M1XoS2lEPTB;ND6zJI5O MVeyNFA3QDB6MB?=
Jeko-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEewR|UzNTVyIH7N MneyNlQhcA>? MX;JR|UxRTFzIH7N MWSyNFA3QDB6MB?=
Granta-519 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTPOU01OCCwTR?= NHXVXG4zPCCq MljzTWM2OD13OD61JI5O MmHYNlAxPjhyOEC=
L1236 MnTwR5l1d3SxeHnjbZR6KEG|c3H5 MWKxJI5ONTFyMDFOwG0> MWq0PEBp NXHKOoFRTUN3ME2wMlA4KM7:TR?= NF:5U5UyQTJ|M{S3NC=>
L428 NEXnWm5EgXSxdH;4bYNqfHliQYPzZZk> MXixJI5ONTFyMDFOwG0> M{LlfFQ5KGh? MXjFR|UxRTBwNEOg{txO MUixPVI{OzR5MB?=
KM-H2 NH7UW2VEgXSxdH;4bYNqfHliQYPzZZk> NU\WUmJzOSCwTT2xNFAh|ryP MWO0PEBp NYrReIFlTUN3ME2wMlU5KM7:TR?= NFT3PIkyQTJ|M{S3NC=>
L540Cy M1S5[GN6fG:2b4jpZ4l1gSCDc4PhfS=> M37tVVEhdk1vMUCwJO69VQ>? NXm0ZlRKPDhiaB?= MkHFSWM2OD1yLkG2JO69VQ>? M{L2SFE6OjN|NEew
G401 MVzGeY5kfGmxbjDBd5NigQ>? NEDXXVUyOCCwTR?= MljsNlQwPDhxN{KgbC=> NHnyNJZFVVOR MVLpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NWLzS5J5OTl{MkG1PFY>
STM91-01 M3PO[mZ2dmO2aX;uJGF{e2G7 NYLWVpBtOTBibl2= MUOyOE81QC95MjDo M1vmfWROW09? NHrDSmZqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NYm5Z4FqOTl{MkG1PFY>
SJSC  MUTGeY5kfGmxbjDBd5NigQ>? MlvxNVAhdk1? MkjXNlQwPDhxN{KgbC=> MmjmSG1UVw>? NUfNT|FNcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NF7a[XUyQTJ{MUW4Oi=>
BT16  NXrKXXFlTnWwY4Tpc44hSXO|YYm= NVnKU4piOTBibl2= M1fzV|I1NzR6L{eyJIg> NV3ZdHJTTE2VTx?= M3TRXYlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NHHPco8yQTJ{MUW4Oi=>
NCI-H1299 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xcmlEPTB;ND62xtExNjJibnevcYw> MlPrNVkyPzl6OUC=
NCI-2882 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCU2lEPTB;MT62xtExNjB2IH7nM41t MUexPVE4QTh7MB?=
HCC95 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGwcYg5UUN3ME2yMlXDuTBwMEWgcocwdWx? M1Tu[|E6OTd7OEmw
NCI-H23 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlztTWM2OD1{LkpCtVAvOiCwZz;tcC=> M1PacVE6OTd7OEmw
NCI-H157 NFfSRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHQbINHUUN3ME2xMlbDuTBwMEKgcocwdWx? Mnq2NVkyPzl6OUC=
NCI-H460 NYXJWHE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSwVZRoUUN3ME2yMlHDuTBwMEegcocwdWx? MWCxPVE4QTh7MB?=
NCI-H1975 Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TGSmlEPTB;MT6zxtExNjB2IH7nM41t MWCxPVE4QTh7MB?=
NCI-H820 M1TNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNNMxNE4yKG6pL33s NWP1coNnOTlzN{m4PVA>
NCI-H1650 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HJUGlEPTB;ND65xtExNjNibnevcYw> MmHxNVkyPzl6OUC=
DTC1 NGS0eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNUGgcm0> Mlm0NVg2PjZ{NE[=
KAO NFi5R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz4VXJKSzVyPUCuPVEhdk1? M2LtWlE5PTZ4MkS2
SU-CCS-1 M4nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fFWGlEPTB;MD64PUBvVQ>? M2rwR|E5PTZ4MkS2
SYO-1 M3q5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVTVBYUUN3ME2wMlY4KG6P NHnIPWkyQDV4NkK0Oi=>
FUJI NELOSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnrdWVJUUN3ME2xMlMyKG6P M13LVVE5PTZ4MkS2
SKNMC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLrfFN7UUN3ME2xMlE4KG6P MWCxPFU3PjJ2Nh?=
402-91 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLKTFVKSzVyPUGuNlYhdk1? Mnq2NVg2PjZ{NE[=
1765-92 M{fxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPhcFVoUUN3ME2xMlc4KG6P M3f0dlE5PTZ4MkS2
JN-DSRCT-1 NX;WOWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi1PVFVUUN3ME2xMlI2KG6P MVKxPFU3PjJ2Nh?=
NMS-2PC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\YT2lEPTB;MD64NUBvVQ>? NGTqT2syQDV4NkK0Oi=>
HL60 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwOE[gcm0> Mn7ZNVg2PjZ{NE[=
A549 NEWwcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\JfGlEPTB;Mz6yOEBvVQ>? MoLxNVg2PjZ{NE[=
SW480 M1y1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnl[YhKSzVyPUKuOlkhdk1? MkfxNVg2PjZ{NE[=
MCF7 NWO3eIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP2TWM2OD1|LkW1JI5O Ml30NVg2PjZ{NE[=
PC-3 NEXOPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrhXG5{UUN3ME2yMlUyKG6P NITZV|IyQDV4NkK0Oi=>
MMRU MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nh[WlEPTB;Mj61O{BvVQ>? NYHsd3JkOTh3Nk[yOFY>
Hs68 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxb|BKSzVyPU6xNEBvVQ>? M1fHR|E5PTZ4MkS2
hMSC-001F Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7MTWM2OD1-MUCgcm0> MXGxPFU3PjJ2Nh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

- 合併
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

- 合併
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2
NCT02393794 Recruiting Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab Triple-Negative Breast Cancer|Breast Cancer Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center July 17 2015 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID